Boehringer Ingelheim International GmbH / T3 Pharmaceuticals AG

Advanced solid tumors (bacterial immunotherapy platform)

600K US cases/yr · $138.0B Global immuno-oncology market forecast (2030) · 508 Total BI-T3 acquisition value (CHF 450M ~ USD MM)

Disease Overview

Advanced solid tumors encompass cancers diagnosed at or progressing to Stage IV — metastatic disease beyond the primary organ. Approximately 1.9 million new cancer cases are diagnosed in the US annually (ACS 2024), of which roughly 30-40% are diagnosed at or progress to advanced/metastatic stage, creating an addressable pool of approximately 600,000 patients per year. Five-year survival for metastatic disease remains poor across most tumor types: metastatic pancreatic cancer ~3%, NSCLC ~8%, colorectal ~15%, gastric ~6%. Checkpoint inhibition (anti-PD-1/PD-L1) has transformed outcomes in melanoma, NSCLC, renal cell carcinoma, MSI-high tumors and certain HCC and urothelial cancers, but the majority of solid-tumor patients are primary or acquired non-responders. 'Cold' tumors with low T-cell infiltration and immunosuppressive microenvironments are the commercial frontier. Engineered live bacterial therapies, including attenuated Yersinia enterocolitica that uses the type III secretion system to deliver immunomodulatory payloads in situ, represent a platform modality aiming to convert cold tumors to hot. Global immuno-oncology market was approximately $64B in 2023 and is forecast to reach $138B by 2030.

Competitive Landscape

Immuno-oncology for 'cold' solid tumors is pharma's highest-stakes modality race, and engineered bacterial therapy is among the most contrarian bets in the field. Approved checkpoint inhibitors: Keytruda (pembrolizumab, Merck, ~$25B 2023), Opdivo (nivolumab, Bristol Myers Squibb, ~$9B), Yervoy (ipilimumab, BMS), Tecentriq (atezolizumab, Roche), Imfinzi (durvalumab, AstraZeneca) and Libtayo (cemiplimab, Regeneron). LAG-3 combination: Opdualag (nivolumab plus relatlimab, BMS). TIGIT: vibostolimab (Merck, Phase 3 setbacks) and domvanalimab (Arcus/Gilead, Phase 3). Engineered bacterial therapies: BI's T3P-Y058-739 (attenuated Yersinia enterocolitica delivering RIG-I CARD/cGAS payloads via a type III secretion system), plus competitors including BioAtla's conditionally active biologics approach, Synlogic's SYNB1891 (E. coli STING agonist, discontinued 2022), and preclinical programs from Prokarium (Salmonella chassis), Ginkgo Bioworks/Motif and academic collaborations. Oncolytic virus comparators: Imlygic (talimogene laherparepvec, Amgen, approved in melanoma) and RP1/RP2 (Replimune, late-stage). T-cell engagers and cell therapies such as Kymriah, Yescarta, Carvykti and Tecvayli bracket the rest of the immunotherapy stack for hematologic indications. BI's T3 acquisition is a platform bet that leverages the multi-year BI-T3 research partnership dating to 2018 and gives BI a non-checkpoint modality positioned for combination with its internal TGF-beta trap, SOS1 and MDM2 inhibitor programs.